BIOFRONTERA BIOSCIENCE GMBH has a total of 31 patent applications. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and micro-structure and nano-technology are SARUDBHAVA FORMULATIONS PRIVATE LTD, BIOSPHERE MEDICAL S A and VITAMIN C60 BIORES KK.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Australia | 4 | |
#5 | Israel | 2 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | Chile | 1 | |
#9 | China | 1 | |
#10 | Mexico | 1 | |
#11 | New Zealand | 1 | |
#12 | Singapore | 1 | |
#13 | Ukraine | 1 | |
#14 | Uruguay | 1 | |
#15 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Micro-structure and nano-technology | |
#4 | Medical technology | |
#5 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Foguet Roca Montserrat | 9 |
#2 | Luebbert Hermann | 6 |
#3 | Schmitz Beate | 4 |
#4 | Roca Montserrat Foguet | 4 |
#5 | Lübbert Hermann | 3 |
#6 | Goppelt Andreas | 3 |
#7 | Sych Michael | 3 |
#8 | Froimowitz Mark | 2 |
#9 | Gordon Douglas | 2 |
#10 | Bellott Emile | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020244751A1 | Illumination for photodynamic therapy | |
AU2018437303A1 | Photodynamic therapy comprising two light exposures at different wavelengths | |
EP2986606A1 | Salt polymorph of thioxanthene-9-ylidene-1-methyl piperidine acid addition salts as antimigraine compounds | |
WO2014117863A1 | Salt polymorph of thioxanthene - 9 - ylidene - 1 - methyl piperidine acid addition salts as antimigraine compounds | |
US2011250239A1 | Pharmaceutical and/or cosmetic composition for treating the skin | |
AU2008200878A1 | Use of a topical medicament comprising riluzole | |
EP1938801A1 | Nanoemulsion | |
EP1477166A1 | The use of riluzol combined with excipients and additives for the treatment of disorders characterised by hyperproliferation of keratinocytes, in particular neurodermitis and psoriasis | |
US7060711B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |